A review of the herbal phosphodiesterase inhibitors; Future perspective of new drugs

Cytokine

Volumn 49, Issue 2, 2010, Pages 123-129

  Rahimi, Roja ^a   Ghiasi, Sima ^a   Azimi, Hanieh ^a   Fakhari, Sima ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cAMP; cGMP; Natural; Phosphodiesterase inhibitors

Indexed keywords

ALKALOID DERIVATIVE; BAY 73 6691; CAFFEINE; COUMARIN DERIVATIVE; ENOXIMONE; ERYTHRO 9 (2 HYDROXYL 3 NONYL)ADENINE; ESSENTIAL OIL; FLAVONOID; HERBACEOUS AGENT; IBUDILAST; ISOBUTYLMETHYLXANTHINE; LIGNAN DERIVATIVE; MESEMBRINE; MILRINONE; PHOSPHODIESTERASE I INHIBITOR; PHOSPHODIESTERASE II INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IX INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PHOSPHODIESTERASE VIII INHIBITOR; PHOSPHODIESTERASE X INHIBITOR; ROLIPRAME; SAPONIN DERIVATIVE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CARDIOVASCULAR DISEASE; DRUG APPROVAL; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DYSPEPSIA; ENZYME ACTIVITY; HOT FLUSH; HUMAN; IN VITRO STUDY; NAUSEA; NONHUMAN; PHYTOTHERAPY; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RASH; REVIEW; SIDE EFFECT; STANDARDIZATION; STRUCTURE ANALYSIS; VOMITING;

DRUG DESIGN; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 73649089598     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.005     Document Type: Review

References (117)

1. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ Res 100 (2007) 309-327
2. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58 (2006) 488-520
3. Kotera J., Sasaki T., and Omori K. Recent progress in cyclic nucleotide phosphodiesterase research: isozymes, function, and inhibitors. Nippon Yakurigaku Zasshi 126 (2005) 121-127
4. Beavo J.A., Conti M., and Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46 (1994) 399-405
5. Uckert S., Kuthe A., Stief C.G., and Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol 19 (2001) 14-22
6. Dousa T.P. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 55 (1999) 29-62
7. Puzzo D., Sapienza S., Arancio O., and Palmeri A. Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 4 (2008) 371-387
8. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65 (2001) 1-52
9. Essayan D.M. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 57 (1999) 965-973
10. Boswell-Smith V., Spina D., and Page C.P. Phosphodiesterase inhibitors. Br J Pharmacol 147 (2006) S252-S257
11. Domek-Łopacińska K., and Strosznajder J.B. Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol 56 (2005) S15-S34
12. Milani E., Nikfar S., Khorasani R., Zamani M.J., and Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 140 (2005) 251-255
13. Mashayekhi F., Aghahoseini F., Rezaie A., Zamani M.J., Khorasani R., and Abdollahi M. Alteration of cyclic nucleotides levels and oxidative stress in saliva of human subjects with periodontitis. J Contemp Dent Pract 6 (2005) 46-53
14. Abdollahi M., Fooladian F., Emami B., Zafari K., and Bahreini-Moghadam A. Protection by sildenafil and theophylline of lead acetate-induced oxidative stress in rat submandibular gland and saliva. Hum Exp Toxicol 22 (2003) 587-592
15. Abdollahi M., Bahreini-Moghadam A., Emami B., Fooladian F., and Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp Biochem Physiol C Toxicol Pharmacol 135 (2003) C331-C336
16. Domek-Łopacińska K., and Strosznajder J.B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216 (2008) 68-77
17. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45 (2004) 915-928
18. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., and Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 202 (2009) 419-443
19. Jeon Y.H., Heo Y.S., Kim C.M., Hyun Y.L., Lee T.G., Ro S., et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62 (2005) 1198-1220
20. Hood W.B. Controlled and uncontrolled studies of phosphodiesterases 3 inhibitors in contemporary cardiovascular medicine. Am J Cardiol 63 (1989) 46A-53A
21. Amsallem E., Kasparian C., Haddour G., Boissel J.P., and Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 1 (2005) CD002230
22. Huang Z., Ducharme Y., Macdonald D., and Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5 (2001) 432-438
23. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1 (2002) 674-682
24. Travadi J.N., and Patole S.K. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 36 (2003) 529-535
25. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., and Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement: a review. Psychopharmacology (Berl) 202 (2009) 419-443
26. Schmidt D., Dent G., and Rabe K.F. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 29 (1999) 99-109
27. Kid P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 4 (1999) 144-161
28. Podzuweit T., Nennstiel P., and Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 7 (1995) 733-738
29. Zhu J., Mix E., and Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev 7 (2001) 387-398
30. Dyke H.J., and Montana J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11 (2002) 1-13
31. Gresser U., and Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature. Eur J Med Res 7 (2002) 435-446
32. Moreira Jr. S.G., Brannigan R.E., Spitz A., Orejuela F.J., Lipshultz L.I., and Kim E.D. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 56 (2000) 474-476
33. Yan C., Zhao A.Z., Bentley J.K., and Beavo J.A. The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271 (1996) 25699-25706
34. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
35. Hindmarch I., Fuchs H.H., and Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6 (1991) 31-43
36. Nicholson C.D. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101 (1990) 147-159
37. Mery P.F., Pavoine C., Pecker F., and Fischmeister R. EHNA as an inhibitor of PDE2: a pharmacological and biochemical study in cardiac myocytes. In: Schudt C., Dent G., and Rabe K.F. (Eds). Phosphodiesterase inhibitors (1996), Academic Press, New York 81-88
38. Loughney K., Hill T.R., Florio V.A., Uher L., Rosman G.J., Wolda S.L., et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216 (1998) 139-147
39. Kotera J., Fujishige K., and Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. J Histochem Cytochem 48 (2000) 685-693
40. Cote R.H. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res 16 (2004) S28-S33
41. Vijayakrishnan L., Rudra S., Eapen M.S., Dastidar S., and Ray A. Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation. Expert Opin Investig Drugs 16 (2007) 1585-1599
42. Giembycz M.A., and Smith S.J. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?. Curr Pharm Des 12 (2006) 3207-3220
43. + T-lymphocytes. Mol Pharmacol 66 (2004) 1679-1689
44. Vergne F., Bernardelli P., Lorthiois E., Pham N., Proust E., Oliveira C., et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: Design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 14 (2004) 4607-4613
45. Barnes M.J., Cooper N., Davenport R.J., Dyke H.J., Galleway F.P., Galvin F.C., et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 11 (2001) 1081-1083
46. Wang H., Yan Z., Yang S., Cai J., Robinson H., and Ke H. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 47 (2008) 12760-12768
47. Wunder F., Tersteegen A., Rebmann A., Erb C., Fahrig T., and Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68 (2005) 1775-1781
48. Wang H., Liu Y., Hou J., Zheng M., Robinson H., and Ke H. Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci USA 104 (2007) 5782-5787
49. Makhlouf A., Kshirsagar A., and Niederberger C. Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res 18 (2006) 501-509
50. Hamburger M. Hostettmann K: bioactivity in plants: the link between phytochemistry and medicine. Phytochemistry 1212 (1991) 3864-3874
51. Kühnau J. The flavonoids, a class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 24 (1976) 117-191
52. Peterson J., and Dwyer J. Flavonoids, dietary occurrence and biochemical activity: a review. Nutr Res 18 (1998) 1995-2018
53. Chen Y.T., Zheng R.L., Jia Z.J., and Ju Y. Flavonoids as super oxide scavengers and antioxidant. Free Radic Biol Med 9 (1990) 19-21
54. Ferrándiz M.L., and Alcaraz M.J. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoid. Agents Actions 32 (1991) 283-288
55. Mehon L.G., Kuttan R., and Kuttan G. Inhibition of long metabolism in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 95 (1995) 221-225
56. Edenhardder R., Von Petersdorff I., and Rauscher R. Antimutagenic effects of flavonoids, chalcones and structurally related compounds on the activity of 2-amino-3-methylimidazole [4,5-f]quinoline (IQ) and other heterocyclic amine mutagens from cooked food. Mutat Res 287 (1993) 261-274
57. Maschi O., Cero E.D., Galli G.V., Caruso D., Bosisio E., and Dell'Agli M. Inhibition of human cAMP-phosphodiesterase as a mechanism of the spasmolytic effect of Matricaria recutita L. J Agric Food Chem 56 (2008) 5015-5020
58. Clack W., and Mackay E. Effect of flavonoid substances on histamine toxicity, anaphylactic shock and histamine enhanced capacity to dye. J Allergy 21 (1950) 133-147
59. Hertog M.G., Hollman P.C., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20 (1993) 21-29
60. Andersen Ø.M., and Markham K.R. Flavonoids chemistry, biochemistry and application (2005), CRC Press
61. Hayashi T., Sawa K., Kawasaki M., Arisawa M., Shimizu M., and Morita N. Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod 51 (1988) 345-348
62. Ferriola P.C., Cody V., and Middleton Jr. E. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 38 (1989) 1617-1624
63. Kuppusamy U.R., and Das N.P. Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. Biochem Pharmacol 44 (1992) 1307-1315
64. Nikaido T., Ohmoto T., Kinoshita T., Sankawa U., Delle Monache F., Botta B., et al. Inhibition of adenosine 3′,5′-cyclic monophosphate phospho diesterase by flavonoids III. Chem Pharm Bull (Tokyo) 37 (1989) 1392-1395
65. Orallo F., Camiña M., Alvarez E., Basaran H., and Lugnier C. Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (±)-naringenin. Planta Med 71 (2005) 99-107
66. Ning H., Xin Z.C., Lin G., Banie L., Lue T.F., and Lin C.S. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology 68 (2006) 1350-1354
67. Nagai H., He J.X., Tani T., and Akao T. Antispasmodic activity of licochalcone A, a species-specific ingredient of Glycyrrhiza inflanta roots. J Pharm Pharmacol 59 (2007) 1421-1426
68. Liu B., Yang J., Wen Q., and Li Y. Isoliquiritigenin, a flavonoid from licorice, relaxes guinea-pig tracheal smooth muscle in vitro and in vivo: role of cGMP/PKG pathway. Eur J Pharmacol 587 (2008) 257-266
69. Ko W.C., Chen M.C., Wang S.H., Lai Y.H., Chen J.H., and Lin C.N. 3-O-Methylquercetin more selectively inhibits phosphodiesterase subtype3. Planta Med 69 (2003) 310-315
70. Shin H.J., Kim H.J., Kwak J.H., Chun H.O., Kim J.H., Park H., et al. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett 12 (2002) 2313-2316
71. Lines T.C., and Ono M. FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A). Phytomedicine 13 (2006) 236-239
72. Sánchez-Mendoza M.E., Torres G., Arrieta J., Aguilar A., Castillo-Henkel C., and Navarrete A. Mechanisms of relaxant action of a crude hexane extract of Gnaphalium liebmanni in guinea pig tracheal smooth muscle. J Ethnopharmacol 111 (2007) 142-147
73. Dell'Agli M., Galli G.V., Vrhovsek U., Mattivi F., and Bosisio E. In vitro inhibition of human cGMP-specific phosphodiesterase-5 by polyphenols from red grapes. J Agric Food Chem 53 (2005) 1960-1965
74. Temkitthawon P., Viyoch J., Limpeanchob N., Pongamornkul W., Sirikul C., Kumpila A., et al. Screening for phospho diesterase inhibitory activity for Thai medicinal plants. J Ethnopharmacol 119 (2008) 214-217
75. Chaabi M., Antheaume C., Weniger B., Justiniano H., Lugnier C., and Lobstein A. Inhibition of human cAMP-phosphodiesterase as a mechanism of the spasmolytic effect of Matricaria recutita L. J Agric Food Chem 56 (2008) 5015-5020
76. Verma S.K., Jain V., Verma D., and Khamesra R. Crataegus oxyacantha: a cardioprotective herb. J Herb Med Toxicol 1 (2007) 65-71
77. Cherdshewasart W., and Nimsakul N. Clinical trial of Butea superb, an alternative herbal treatment for erectile dysfunction. Asian J Androl 5 (2003) 243-246
78. Chit K., Myint W., Theine K., Maw W., Myint M., Than A., et al. Cyclic AMP phosphodiesterase inhibitory activity and chemical screening of four medicinal plants. Pharm Biol 39 (2001) 181-183
79. Nishibe S. Bioactive phenolic compounds in traditional medicines. Pure Appl Chem 66 (1994) 2263-2266
80. Macovschi O., Prigent A.F., Nemoz G., and Pacheco H. Effects of an extract of Ginkgo biloba on the 3′,5′-cyclic AMP phosphodiesterase activity of the brain of normal and triethyltin-intoxicated rats. J Neurochem 49 (1987) 107-114
81. Sousa Falcão H., Leite J.A., Barbosa-Filho J.M., de Athayde-Filho P.F., de Oliveira Chaves M.C., Moura M.D., et al. Gastric and duodenal antiulcer activity of alkaloids: a review. Molecules 13 (2008) 3198-3223
82. Kaufman P.B., Cseke L.J., Warber S., Duke J.A., and Brielmann H.L. Natural products from plants (1999), CRC Press, USA
83. Ohmoto T., Nikaido T., Koike K., Kohda K., and Sankawa U. Inhibition of adenosine 3′,5′-cyclic monophosphate phosphodiesterase by alkaloids II. Chem Pharm Bull (Tokyo) 36 (1988) 4588-4592
84. Chen J., Liu J.H., Wang T., Xiao H.J., Yin C.P., and Yang J. Effects of plant extract neferine on cyclic adenosine monophosphate and guanosine monophosphate levels in rabbit corpus cavernosum in vitro. Asian J Androl 10 (2008) 307-312
85. Hwang T.L., Leu Y.L., Kao S.H., Tang M.C., and Chang H.L. Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway. Free Radic Biol Med 41 (2006) 1433-1441
86. Oleszek W., Jurzysta M., Ploszynski M., Colquhoun I.J., Price K.R., and Fenwick G.R. Zahnic acid trides moside and other dominant saponins from alfalfa (Medicago sativa L.) aerial parts. J Agric Food Chem 4 (1992) 191-196
87. Watanabe M., Sumida N., Yanai K., and Murakami T. A novel saponin hydrolase from Neocosmospora vasinfecta var. vasinfecta. Appl Environ Microbiol 70 (2004) 865-872
88. Lasztity R., Hidevegi M., and Bata A. Saponins in food. Food Rev Int 14 (1998) 371-390
89. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58 (1999) 1685-1693
90. Ahn K.S., Kim J.H., Oh S.R., Min B.S., Kinjo J., and Lee H.K. Effects of oleanane-type triterpenoids from fabaceous plants on the expression of ICAM-1. Biol Pharm Bull 25 (2002) 1105-1107
91. Berhow M.A., Wagner E.D., Vaughn S.F., and Plewa M.J. Characterization and antimutagenic activity of soybean saponins. Mutat Res 448 (2000) 11-22
92. Kinjo J., Yokomizo K., Hirakawa T., Shii Y., Nohara T., and Uyeda M. Anti-herpes virus activity of fabaceous triterpenoidal saponins. Biol Pharm Bull 23 (2000) 887-889
93. Miura N., Matsumoto Y., Miyairi S., Nishiyama S., and Naganuma A. Protective effects of triterpene compounds against the cytotoxicity of cadmium in HepG2 cells. Mol Pharmacol 56 (1999) 1324-1328
94. Sasaki K., Minowa N., Kuzuhara H., Nishiyama S., and Omoto S. Synthesis and hepatoprotective effects of soyasapogenol B derivatives. Bioorg Med Chem Lett 7 (1997) 85-88
95. Maes L., Germonprez N., Quirijnen L., Van Puyvelde L., Cos P., and Vanden Berghe D. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob Agents Chemother 48 (2004) 2056-2060
96. Mimaki Y., Sashida Y., Nakamura O., Nikaido T., and Ohmoto T. Steroidal saponins from the bulbs of Lilium regale and L. henryi. Phytochemistry 33 (1993) 675-682
97. + ATPase. Phytochemistry 40 (1995) 1071-1076
98. Ikeda Y., Sugiura M., Fukaya C., Yokoyama K., Hashimoto Y., Kawanishi K., et al. Periandradulcins A, B and C: phosphodiesterase inhibitors from Periandra dulcis Mart. Chem Pharm Bull (Tokyo) 39 (1991) 566-571
99. William Charles Evans, George Edward Trease, Daphne Evans. 15th ed. USA: W.B. Saunders; 2002.
100. Deyama T., Ikawa T., Kitagawa S., and Nishibe S. The constituents of Eucommia ulmoides. Oliv. V: isolation of dihydroxydehydrodi coniferyl alcohol isomers and phenolic compounds. Chem Pharm Bull 35 (1987) 1785-1789
101. Nikaido T., Ohmoto T., Noguchi H., Kinoshita T., Saitoh H., and Sankawa U. Inhibitors of cyclic AMP phosphodiesterase in medicinal plants. Planta Med 43 (1981) 18-23
102. Borges F., Roleira F., Milhazes N., Santana L., and Uriarte E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 12 (2005) 887-916
103. Hoult J.R., and Payá M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 27 (1996) 713-722
104. Sato Y., Akao T., He J.X., Nojima H., Kuraishi Y., Morota T., et al. Glycycoumarin from Glycyrrhizae Radix acts as a potent antispasmodic through inhibition of phosphodiesterase 3. J Ethnopharmacol 105 (2006) 409-414
105. Chen J., Chiou W.F., Chen C.C., and Chen C.F. Effect of the plant-extract osthole on the relaxation of rabbit corpus cavernosum tissue in vitro. J Urol 163 (2000) 1975-1980
106. Teng C.M., Lin C.H., Ko F.N., Wu T.S., and Huang T.F. The relaxant action of osthole from Angelica pubescens in guinea-pig trachea. Naunyn Schmiedebergs Arch Pharmacol 349 (1994) 202-208
107. Hnatyszyn O., Moscatelli V., Garcia J., Rondina R., Costa M., Arranz C., et al. Argentinian plant extracts with relaxant effect on the smooth muscle of the corpus cavernosum of guinea pig. Phytomedicine 10 (2003) 669-674
108. Hasani-Ranjbar S., Nayebi N., Larijani B., and Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 5 25 (2009) 3073-3085
109. Hasani-Ranjbar S., Larijani B., and Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets 8 1 (2009) 2-10
110. Rahimi R., Mozaffari S., and Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 54 (2009) 471-480
111. Hasani-Ranjbar S., Larijani B., and Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch Med Sci 4 3 (2008) 285-292
112. Rahimi R., Nikfar S., Larijani B., and Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother 59 7 (2005) 365-373
113. Rezaie A., Parker R.D., and Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?. Dig Dis Sci 52 (2007) 2015-2021
114. Vakilian K., Ranjbar A., Zarganjfard A., Mortazavi M., Vosough-Ghanbari S., Mashaiee S., et al. On the relation of oxidative stress in delivery mode in pregnant women: a toxicological concern. Toxicol Mech Methods 19 2 (2009) 94-99
115. Ansari G., Mojtahedzadeh M., Kajbaf F., Najafi A., Khajavi M.R., Khalili H., et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 25 7 (2008) 681-702
116. Yousefzadeh G., Larijani B., Mohammadirad A., Heshmat R., Dehghan G., Rahimi R., et al. Determination of oxidative stress status and concentration of TGF-β1 in the blood and saliva of osteoporotic subjects. Ann NY Acad Sci 1091 (2006) 142-150
117. Calixto J.B. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res 33 (2000) 179-189